Navigation Links
Local Gastroenterologists First in South Florida to Offer Fecal Transplant
Date:8/7/2012

CORAL SPRINGS, Fla., Aug. 7, 2012 /PRNewswire/ -- Digestive CARE™, a medical group of 52 gastroenterologists in Broward and Palm Beach County, today announced that they are the first gastroenterology group in South Florida to offer Fecal Transplant therapy to patients with Fulminant or Refractory Pseudomembraneous Colitis.

Pseudomembranous colitis has dramatically increased in frequency and severity over the past ten years.  Coincident with this, a dramatic increase has been seen in refractory, relapsing, and fulminant cases.  In addition, a new hypervirulent strain of C. Dif (NAP1/B!/027) has been implicated in several outbreaks since the early 2000's.  This strain may be particularly refractory to standard antibiotic treatment.  As many as 11% of patients infected with the hypervirulent strain of C. Dif may experience complications including shock, need for colectomy, megacolon, perforation and even death within a 30 day period.  Gastroenterologists have all experienced diminishing returns with standard antibiotic protocols.

Fecal bacteriotherapy (i.e. fecal transplant) involves instillation of healthy donor stool via colonoscope, enema, or nasojejunal tube into the alimentary tract of the patient.  There are nearly 275 studied cases of fecal bacteriotherapy.  All patients suffered from either refractory, recurrent, or fulminant disease.  Seventy five percent of cases involved instilling donor stool via colonoscopy.  The cumulative success rate in this extremely challenging patient cohort is reported to be 89%.  This success rate reaches 98% when an additional infusion is administered in the few patients who fail to respond to initial treatment.

Digestive CARE™ is pleased to offer this service at Boca Raton Regional Hospital.  Appropriate patients include those with refractory, recurrent, or fulminant disease.  Please see below for inclusion criteria.

  1. Refractory –moderate symptoms not responding to oral vancomycin for at least one week
  2. Recurrent – 3 episodes of mild to moderate C. Dif colitis with failure of a 6-8 week taper of vancomycin OR 2 episodes of severe C. Dif. resulting in hospitalization or significant morbidity.
  3. Fulminant – severe disease (associated with diffuse abdominal pain, fever, acidosis, hypovolemia, significant leukocytosis, megacolon) and no response to standard therapy within 48 hrs.

Patient transfers from other hospitals are accepted for inpatient therapy as well as for outpatients with less severe disease.  Contact Digestive CARE™ today for a referral to a gastroenterologist who performs this procedure at (954) 344-2522 or online at www.digestivecareonline.com.

About Digestive CARE™:
Since its inception as an organization, Digestive CARE™ has grown to 60 providers, 52 of which are physicians, providing gastroenterology services at 25 locations throughout Broward and Palm Beach counties, covering 17 local hospitals and 14 Outpatient Surgery Centers.  All Digestive CARE™ physician office and surgical locations are centers of excellence, designed with the comfort and care of the patient in mind, delivering services in a friendly, convenient and compassionate environment.  For more information, please call (954) 344-2522 or visit www.digestivecareonline.com.

MEDIA CONTACT:
Jennifer Veasey
Digestive CARE™
(954) 344-2522, ext. 333       
jveasey@digestivecareonline.com


'/>"/>
SOURCE Digestive CARE
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First Warning Systems Receives Investment by Members of the Reno Angels and Local Investors
2. Emerging Pharmaceutical Market in Brazil - Regulatory Framework Forces MNCs to Partner with Local Players Resulting in Profit and Control Sharing
3. Medbox, Inc. Rides a Wave of Local Media Support in Connecticut
4. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
5. Cyberonics To Report Fiscal Year 2013 First Quarter Results And Host Conference Call On August 28, 2012
6. Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2012
7. Midwest Health Care Startups Raise $511 Million in First Half of 2012
8. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
9. Target for potent first-strike influenza drugs identified
10. Genelex Receives First Patent on Business Methods for Pharmacogenetics
11. TI introduces the industrys first weigh scale and body composition analog front end
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)...  Consumer reviews on the independent review site Consumer Affairs ... company for hearing aids, ranking it higher than Miracle Ear ... ... For Hearing Aids ... online store that provides high performance, state-of-the-art, German-engineered hearing aids directly ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
Breaking Medicine News(10 mins):